Genomic Health to Present Proof-of-Concept Bladder Cancer Liquid Biopsy Data at AACR Precision Medicine Meeting
Results Demonstrate Company's Progress in Development of Urine Test for Monitoring of Bladder Cancer
REDWOOD CITY, Calif., June 11, 2015 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from a multi-center, proof-of-concept, bladder cancer liquid biopsy study will be presented at the American Association for Cancer Research (AACR) Precision Medicine Meeting in Salt Lake City. The study was co-led by Genomic Health, Vanderbilt University Medical Center, Carolina Urologic Research Center, Associated Medical Professionals of New York, and NorthShore University HealthSystem, and conducted in collaboration with 10 additional sites in the United States.
"The upcoming presentation is an important step for Genomic Health's liquid biopsy program as we continue to develop non-invasive cancer tests," said Ellen Beasley, Ph.D., senior vice president, Research and Development, Genomic Health.
The American Bladder Cancer Society estimates that over 72,000 men and women will be diagnosed with bladder cancer each year in the United States. A man's chance of getting bladder cancer in his lifetime is 1 in 26, while a woman's is 1 in 90. Currently, bladder cancer surveillance is performed via a cystoscopy – an invasive procedure that uses an instrument equipped with a camera and light to look at the inside of the bladder.
The poster, titled "Analysis of tumor DNA in urine as a highly sensitive liquid biopsy for patients with non-muscle invasive bladder cancer," will be presented on Monday, June 15, from 12-3 p.m. in the Grand Ballroom at the Grand America Hotel.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the value and benefits of urine-based monitoring of bladder cancer patients; the expectation that the test results could enable a urine-based test for monitoring bladder cancer recurrence in early-stage patients, and the potential benefits of such a test; and the company's belief that the study results demonstrate continued progress toward development of non-invasive tests for individualized treatment at various stages of disease. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the company's ability to develop and commercialize new tests, including tests based on liquid biopsy; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the quarter ended March 31, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
SOURCE Genomic Health, Inc.
Share this article